Corrigendum: Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors

In the published article, there was an error in the legend for Figure 1 as published. We mistaken referred to the tumor models as xenografts instead of syngeneic models in the sentence: “We first compared different oHSV constructs for their ability to kill MPNST cells and shrink MPNST xenografts.”

The corrected legend appears below.

The experimental design used in this report. We first compared different oHSV constructs for their ability to kill MPNST cells and shrink MPNST syngeneic tumors. As none of the viruses was consistently superior to the others, we chose the FDA-approved virus, T-VEC, to further study in combination with drugs postulated to enable viroimmunotherapy. Because in other studies we found trabectedin to be toxic to C57Bl/6 animals, we pivoted to an MPNST model in the Balb/c background to test that combination.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.